A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers

This study has been completed.
Sponsor:
Information provided by:
Labopharm Inc.
ClinicalTrials.gov Identifier:
NCT00834808
First received: January 30, 2009
Last updated: April 24, 2012
Last verified: April 2012
  Purpose

The purposes of this study were:

  • To evaluate the plasma pharmacokinetic profile of tramadol and its principal metabolite, the O-desmethyltramadol, after a single oral administration of 100, 200 and 300 mg of tramadol as the Labopharm extended-release formulation prepared with Contramid.
  • To assess the dose linearity of tramadol and its principal metabolite, the O-desmethyltramadol, between 100 mg and 300 mg following a single dose administration of the Labopharm extended-release formulation prepared with Contramid under fasting conditions in young healthy volunteers.

Condition Intervention Phase
Healthy
Drug: Tramadol HCl
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label

Resource links provided by NLM:


Further study details as provided by Labopharm Inc.:

Primary Outcome Measures:
  • AUC(0-t) [ Time Frame: 48 hours ] [ Designated as safety issue: No ]

    Area under the plasma concentration versus time curve to the last measurable concentration.

    h = hours


  • AUC(0-inf) [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Area under the plasma concentration versus time curve extrapolated to infinity. h = hours

  • Cmax [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Maximum plasma concentration.


Secondary Outcome Measures:
  • Tmax [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Time to maximum plasma concentration

  • t1/2 [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Apparent terminal elimination half-life


Enrollment: 27
Study Start Date: November 2002
Study Completion Date: December 2002
Primary Completion Date: December 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1: Tramadol HCl 100mg Drug: Tramadol HCl
One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
Other Name: Tramadol HCl
Experimental: 2: Tramadol HCl 200mg Drug: Tramadol HCl
One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
Other Name: Tramadol HCl
Experimental: 3: Tramadol HCl 300mg Drug: Tramadol HCl
One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
Other Name: Tramadol HCl

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by the informed consent form duly signed by the subject.
  • Males aged from 18 to 45 years inclusively and with Body Mass Index (BMI) between 18 and 30 kg/m2 inclusively.
  • Clinical laboratory values within 10% above or below the laboratory's stated normal range; if not within this range, the clinical investigator will decide if they were not clinically significant and recorded this fact on the Case Report Form (CRF).
  • Healthy according to the physical examination and laboratory results.
  • Normal cardiovascular function according to a 12-lead electrocardiogram (ECG).
  • Non-smoker or subjects smoking no more than 5 cigarettes per day (or equivalent) and able to abstain from smoking during inpatient phases of the study.
  • Subjects covered by Social Security in compliance with the recommendations of French Law relating to biomedical research.
  • Subjects with normal dietary requirements (neither vegetarian, nor on a diet).

Exclusion Criteria:

  • History of hypersensitivity to tramadol or any other compounds.
  • Presence or significant history of gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  • Presence or significant history of cardiovascular, pulmonary, haematological, neoplasic, neurological, psychiatric, endocrine, immunological or dermatological disease.
  • Presence or significant history of glaucoma.
  • Supine pulse rate lower than 45 beats per minute (bpm) after 5 minutes at rest or higher than 100 bpm.
  • History of hypotensive episodes or a standing systolic blood pressure reading of <100 mmHg or a diastolic reading of <45 mmHg, measured on the screening day.
  • History of hypertensive episodes or a supine systolic blood pressure reading of >145 mmHg or a diastolic reading of >95 mmHg, measured on the screening day.
  • Presence of atrioventricular (AV) block assessed during pre-study evaluation or during the study. The lower limit considered for a first degree AV block was be a PR interval of 200 millisecond (msec).
  • Maintenance therapy with any drug, or history of drug dependency, alcohol abuse (>3 units of alcohol per day), or serious psychological disease.
  • Subjects consuming large quantities of drinks containing xanthine bases (coffee, tea, chocolate or cola; more than 6 cups or glasses per day).
  • Any clinically significant illness in the previous 21 days before day 1 of this study.
  • Subjects who had undergone general anesthesia within 3 months prior to the present study.
  • Use of drugs known to affect liver enzymes (eg, inducers or inhibitors of Cytochrome P450) in the previous 30 days before day 1 of this study (eg, all barbiturates, corticosteroids, di & methyl-phenylhydantoin).
  • Use of any medication (including OTC preparations) in the previous 14 days before day 1 of this study.
  • Donation of 350 mL (or more) of blood in the previous 3 months or participation in another clinical trial in the previous 3 months before day 1 of this study.
  • Subjects undergoing dental care.
  • Positive urine drug screening.
  • Positive results to human immunodeficiency virus (HIV) 1 & 2 or hepatitis B surface antigen (HBsAg) or anti-HCV (hepatitis C virus) tests.
  • History of fainting upon blood sampling.
  • Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of the consent to participate in the study or to limit the ability to comply with the protocol requirements.
  • Subjects unable to abstain from intensive muscular effort or sport competitions during the week prior to the study and throughout the study itself.
  • Subjects who had forfeited his freedom by administrative or legal award or who were under guardianship.
  • Subjects who received the ceiling amount of 25,000 francs within the last 12 months or who reached this ceiling with the payment of this allowance for this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Additional Information:
Publications:
Responsible Party: Vice-President Regulatory Affairs, Labopharm Inc.
ClinicalTrials.gov Identifier: NCT00834808     History of Changes
Other Study ID Numbers: MDT1-011
Study First Received: January 30, 2009
Results First Received: April 8, 2009
Last Updated: April 24, 2012
Health Authority: United States: Food and Drug Administration
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Labopharm Inc.:
Healthy volunteers

Additional relevant MeSH terms:
Tramadol
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 28, 2014